134 related articles for article (PubMed ID: 3071382)
1. Screening for ovarian cancer.
Jacobs I; Oram D
Biomed Pharmacother; 1988; 42(9):589-96. PubMed ID: 3071382
[TBL] [Abstract][Full Text] [Related]
2. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
3. [Early detection and preoperative diagnosis of ovarian carcinoma].
Kainz C
Wien Med Wochenschr; 1996; 146(1-2):2-7. PubMed ID: 8835487
[TBL] [Abstract][Full Text] [Related]
4. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ; Oram DH; Bast RC
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
[TBL] [Abstract][Full Text] [Related]
5. Screening and detection of ovarian cancer.
Breedlove G; Busenhart C
J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
[TBL] [Abstract][Full Text] [Related]
6. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
7. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
[TBL] [Abstract][Full Text] [Related]
8. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
9. ACR appropriateness criteria© ovarian cancer screening.
Brown DL; Andreotti RF; Lee SI; Dejesus Allison SO; Bennett GL; Dubinsky T; Glanc P; Horrow MM; Lev-Toaff AS; Horowitz NS; Podrasky AE; Scoutt LM; Zelop CM
Ultrasound Q; 2010 Dec; 26(4):219-23. PubMed ID: 21084936
[TBL] [Abstract][Full Text] [Related]
10. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
de Bruijn HW; van der Zee AG; Aalders JG
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer. The most lethal gynecologic malignancy.
Brucks JA
Nurs Clin North Am; 1992 Dec; 27(4):835-45. PubMed ID: 1448359
[TBL] [Abstract][Full Text] [Related]
13. [Screening for ovarian cancer].
Bjørge T; Dørum A; Tropé CG
Tidsskr Nor Laegeforen; 2000 May; 120(12):1444-8. PubMed ID: 10851943
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
15. [Screening for ovarian cancers: critical analysis].
Pennehouat G; Gugliemina JN; Naouri M; Créquat J; Bouret JM; Thébault Y; Madelenat P
Contracept Fertil Sex; 1993 Mar; 21(3):223-30. PubMed ID: 7951617
[TBL] [Abstract][Full Text] [Related]
16. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer.
Jacobs I
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S22-7. PubMed ID: 7835805
[No Abstract] [Full Text] [Related]
17. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
18. How relevant are ACOG and SGO guidelines for referral of adnexal mass?
Dearking AC; Aletti GD; McGree ME; Weaver AL; Sommerfield MK; Cliby WA
Obstet Gynecol; 2007 Oct; 110(4):841-8. PubMed ID: 17906018
[TBL] [Abstract][Full Text] [Related]
19. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
20. [Ovarian cancer screening: recommendations for clinical pratice].
Amram-Benamran ML; Cochet S; Petignat P; Sappino AP
Rev Med Suisse; 2010 May; 6(250):1062, 1064, 1066-8. PubMed ID: 20564865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
